AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28396238 — intervention group
Group type: COMPARATOR
Intervention: Low dose low molecular weight heparin (LMWH) alone
Number of subjects: 2236
Study 25975523 — intervention group
Group type: EXPERIMENTAL
Intervention: Breadloaf microscopy
Number of subjects: 553
Study 25975523 — intervention group
Group type: COMPARATOR
Intervention: 3D microscopy
Number of subjects: 553
Study 25975523 — intervention group
Group type: EXPERIMENTAL
Intervention: Breadloaf microscopy (infiltrative/sclerosing/morpheaform tumors)
Number of subjects: 553
Study 25975523 — intervention group
Group type: COMPARATOR
Intervention: 3D microscopy (infiltrative/sclerosing/morpheaform tumors)
Number of subjects: 553
Study 25975523 — intervention group
Group type: EXPERIMENTAL
Intervention: Breadloaf microscopy (solid/nodular tumors)
Number of subjects: 553
Study 25975523 — intervention group
Group type: COMPARATOR
Intervention: 3D microscopy (solid/nodular tumors)
Number of subjects: 553
Study 24524874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 43
Study 24524874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical therapy)
Number of subjects: 43
Study 22033572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (Beconase(®)), 200 μg daily
Number of subjects: 19
Study 22033572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (FESS(®) saline nasal spray)
Number of subjects: 19
Study 20109208 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg for 4 weeks followed by 10 microg)
Number of subjects: 54
Study 20109208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20109208 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 54
Study 18724191 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interview (ACASI) system
Number of subjects: 0
Study 15918622 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting octreotide (100 mcg subcutaneously thrice daily for two weeks, then 20 mg intramuscularly monthly)
Number of subjects: 22
Study 15918622 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting octreotide
Number of subjects: 22
Study 15918622 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients who refused treatment)
Number of subjects: 22
Study 12558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulthiame (STM) monotherapy
Number of subjects: 66
Study 12558577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 10570723 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (n = 6)
Number of subjects: 28
Study 10570723 — intervention group
Group type: COMPARATOR
Intervention: Migraine without aura (n = 13)
Number of subjects: 28
Study 9417493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-selenit 200 micrograms/d
Number of subjects: 70
Study 9417493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline solution with 1% lidocaine with epinephrine 1:300,000
Number of subjects: 0
Study 8383150 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine with epinephrine 1:100,000 with sodium bicarbonate 80 meq/mL
Number of subjects: 0
Study 8383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline solution with 1% lidocaine with epinephrine 1:100,000
Number of subjects: 0
Study 8383150 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine 1:100,000
Number of subjects: 0
Study 3017392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate, 2 g, administered 6 hourly for three doses daily beginning 1 day before DEC was started and continued throughout the DEC therapy.
Number of subjects: 21
Study 3017392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bicarbonate treatment).
Number of subjects: 21
Study 29773717 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors (nivolumab)
Number of subjects: 174
Study 29773717 — intervention group
Group type: EXPERIMENTAL
Intervention: STK11/LKB1 alterations
Number of subjects: 174
Study 29773717 — intervention group
Group type: EXPERIMENTAL
Intervention: Stk11/Lkb1 loss in murine models
Number of subjects: 174
Study 27416024 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Number of subjects: 325
Study 27416024 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus azathioprine (CS+A)
Number of subjects: 325
Study 27416024 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 325
Study 27416024 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 325
Study 24906602 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital drainage systems
Number of subjects: 381
Study 23238355 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg racemic ibuprofen suppository
Number of subjects: 10
Study 23238355 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen syrup
Number of subjects: 10
Study 20479446 — intervention group
Group type: EXPERIMENTAL
Intervention: 870- and 930-nm light exposure treatment
Number of subjects: 26
Study 18303470 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension power (LEP) of the fractured leg
Number of subjects: 43
Study 18303470 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension power (LEP) of the nonfractured leg
Number of subjects: 43
Study 18303470 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical LEP deficit
Number of subjects: 43
Study 18303470 — intervention group
Group type: EXPERIMENTAL
Intervention: LEP of the nonfractured leg at week 1
Number of subjects: 43
Study 16323028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nasal ointment
Number of subjects: 33
Study 16323028 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-use of the test agent)
Number of subjects: 33
Study 12220761 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg
Number of subjects: 260
Study 12220761 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 10 mg
Number of subjects: 260
Study 12220761 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 260
Study 10414911 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/day)
Number of subjects: 46
Study 10414911 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF (500 microg/day)
Number of subjects: 46
Study 10414911 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 46
Study 10414911 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF and GM-CSF
Number of subjects: 46
Study 8600199 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for symptomatic bacteriuria
Number of subjects: 50
Study 8600199 — intervention group
Group type: COMPARATOR
Intervention: No treatment or placebo (Control)
Number of subjects: 50
Study 8358504 — intervention group
Group type: EXPERIMENTAL
Intervention: THA + lecithin
Number of subjects: 17
Study 8358504 — intervention group
Group type: EXPERIMENTAL
Intervention: THA + placebo
Number of subjects: 17
Study 8358504 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 17
Study 8358504 — intervention group
Group type: EXPERIMENTAL
Intervention: THA treatment
Number of subjects: 17
Study 3781699 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline + gentamicin
Number of subjects: 70
Study 3781699 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole + gentamicin
Number of subjects: 70
Study 29551430 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus add-back (Leuprolide depot 11.25 mg intramuscular injection every 3 months, plus oral norethindrone acetate 5 mg daily)
Number of subjects: 51
Study 29551430 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus modified 2-drug add-back regimen (oral norethindrone acetate 5 mg daily and oral conjugated equine estrogens 0.625 mg daily)
Number of subjects: 51
Study 29551430 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus add-back
Number of subjects: 51
Study 29282929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous drip group (group A)
Number of subjects: 68
Study 29282929 — intervention group
Group type: COMPARATOR
Intervention: Topical application group (group B)
Number of subjects: 68
Study 24462480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (parent-student intervention)
Number of subjects: 3490
Study 24462480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3490
Study 23043083 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine dressings
Number of subjects: 1879
Study 23043083 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly adhesive dressings
Number of subjects: 1879
Study 23043083 — intervention group
Group type: COMPARATOR
Intervention: Nonchlorhexidine dressings
Number of subjects: 1879
Study 20875374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 100 mg
Number of subjects: 75
Study 20875374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 150 mg
Number of subjects: 75
Study 20875374 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 75
Study 20875374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 18550935 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ (160/12.5 mg)
Number of subjects: 0
Study 18550935 — intervention group
Group type: COMPARATOR
Intervention: HCTZ (25 mg)
Number of subjects: 0
Study 15345500 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg twice daily
Number of subjects: 970
Study 15345500 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 970
Study 15345500 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 970
Study 12354470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 16
Study 12354470 — intervention group
Group type: COMPARATOR
Intervention: Nitric oxide (10-20 ppm)
Number of subjects: 16
Study 12354470 — intervention group
Group type: COMPARATOR
Intervention: Epoprostenol (mean 8.0 ng/kg per min)
Number of subjects: 16
Study 10748772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg i.v. 5 minutes before induction of anaesthesia (before skin incision)
Number of subjects: 30
Study 10748772 — intervention group
Group type: COMPARATOR
Intervention: Pethidine administered intraoperatively
Number of subjects: 30
Study 10748772 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesic requirements
Number of subjects: 30
Study 8768686 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped music and a message from their physicians during the next four chemotherapy treatments (n = 47)
Number of subjects: 97
Study 8768686 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 50)
Number of subjects: 97
Study 1673587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous xamoterol
Number of subjects: 30
Study 1673587 — intervention group
Group type: COMPARATOR
Intervention: Oral xamoterol, 200 mg twice daily
Number of subjects: 30
Study 1673587 — intervention group
Group type: COMPARATOR
Intervention: Oral xamoterol
Number of subjects: 30
Study 7232091 — intervention group
Group type: EXPERIMENTAL
Intervention: Feingold diet violations
Number of subjects: 0
Study 7232091 — intervention group
Group type: COMPARATOR
Intervention: Noninfraction conditions
Number of subjects: 0
Study 30801699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 101
Study 30801699 — intervention group
Group type: COMPARATOR
Intervention: High-dose adrenocorticotropic hormone (ACTH)
Number of subjects: 101
Study 30801699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) without prior vigabatrin (VGB)
Number of subjects: 101
Study 30801699 — intervention group
Group type: COMPARATOR
Intervention: High-dose adrenocorticotropic hormone (ACTH) without prior vigabatrin (VGB)
Number of subjects: 101
Study 30801699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) with prior vigabatrin (VGB)
Number of subjects: 101
Study 30801699 — intervention group
Group type: COMPARATOR
Intervention: High-dose adrenocorticotropic hormone (ACTH) with prior vigabatrin (VGB)
Number of subjects: 101
Study 27364900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg IR/ER every 12 hours
Number of subjects: 63
Study 27364900 — intervention group
Group type: COMPARATOR
Intervention: Standard ibuprofen 200 mg IR every 4 hours
Number of subjects: 63
Study 27364900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg IR/ER with food
Number of subjects: 63
Study 27364900 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of ibuprofen IR/ER
Number of subjects: 63
Study 25070347 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300mg)
Number of subjects: 32
Study 25070347 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (320mg)
Number of subjects: 32
Study 23662746 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider counseling with supplemental group education (n=112)
Number of subjects: 443
Study 23662746 — intervention group
Group type: COMPARATOR
Intervention: Individual provider counseling (n=331)
Number of subjects: 443
Study 21289620 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral synthetic THC
Number of subjects: 9
Study 21289620 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral synthetic THC
Number of subjects: 9
Study 21289620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Sativex (5.4 mg THC, 5.0 mg CBD)
Number of subjects: 9
Study 21289620 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Sativex (16.2 mg THC, 15.0 mg CBD)
Number of subjects: 9
Study 21289620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice noodles
Number of subjects: 14
Study 19169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-grain rice
Number of subjects: 14
Study 19169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy-cook long-grain rice
Number of subjects: 14
Study 19169946 — intervention group
Group type: EXPERIMENTAL
Intervention: White basmati rice
Number of subjects: 14
Study 19169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Other rice types (white basmati, brown basmati, easy-cook basmati, basmati and wild rice, Thai red rice, Thai glutinous rice)
Number of subjects: 14
Study 19169946 — intervention group
Group type: COMPARATOR
Intervention: Glucose standard
Number of subjects: 14
Study 17665810 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for depressed adolescents (IPT-A)
Number of subjects: 0
Study 15066470 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 11480801 — intervention group
Group type: EXPERIMENTAL
Intervention: Capping punitive damages
Number of subjects: 0
Study 11480801 — intervention group
Group type: EXPERIMENTAL
Intervention: No option to award punitive damages
Number of subjects: 0
Study 9554429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 50
Study 9554429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7825744 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminol‐dependent chemiluminescence (CL) in semen of infertile men
Number of subjects: 49
Study 3240842 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% protein diet (0.9 +/- 0.06 g.kg‐1.day‐1)
Number of subjects: 16
Study 3240842 — intervention group
Group type: COMPARATOR
Intervention: 20% protein diet (1.9 +/- 0.1 g.kg‐1.day‐1)
Number of subjects: 16
Study 3240842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 16
Study 30273290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body fatigue
Number of subjects: 24
Study 29803539 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus illustrated information (pictograms and simple text)
Number of subjects: 116
Study 29803539 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 116
Study 29330997 — intervention group
Group type: EXPERIMENTAL
Intervention: Various Vitamin D3 preparations (Cholecalciferol) administered orally and intramuscularly
Number of subjects: 320
Study 25077885 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 0
Study 23746561 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 0
Study 23746561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23746561 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 21908159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 93
Study 18216316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric gluconate
Number of subjects: 0
Study 18216316 — intervention group
Group type: COMPARATOR
Intervention: Control (no ferric gluconate)
Number of subjects: 0
Study 17023868 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate at titrated doses (average, 14.2 mg/day) administered three times daily, 7 days/week for approximately 1 year
Number of subjects: 140
Study 17023868 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment for 95 children who remained on medication
Number of subjects: 140
Study 12717397 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic regimen
Number of subjects: 36
Study 12717397 — intervention group
Group type: COMPARATOR
Intervention: Endotoxin stimulation
Number of subjects: 36
Study 12717397 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis (baseline)
Number of subjects: 36
Study 10886792 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded sodium stibogluconate (Pentostam)
Number of subjects: 516
Study 10886792 — intervention group
Group type: COMPARATOR
Intervention: Generic sodium stibogluconate (Albert David Ltd)
Number of subjects: 516
Study 8813840 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (20 min/day, 5 days/week bicycle exercise)
Number of subjects: 12
Study 8813840 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 12
Study 8813840 — intervention group
Group type: COMPARATOR
Intervention: Detraining
Number of subjects: 12
Study 1566165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity trunk exercise program (3 sets of 10 repetitions for sit-up, prone trunk extension, and double leg flexion exercises, performed a minimum of three times per week for 1 year)
Number of subjects: 49
Study 1566165 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 3929320 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lithium treatment
Number of subjects: 0
Study 3929320 — intervention group
Group type: COMPARATOR
Intervention: Other psychoactive drugs (not specified)
Number of subjects: 0
Study 30804029 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Curriculum Group
Number of subjects: 36
Study 30804029 — intervention group
Group type: COMPARATOR
Intervention: Conventional Curriculum Group
Number of subjects: 36
Study 29198730 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention
Number of subjects: 2655
Study 29198730 — intervention group
Group type: COMPARATOR
Intervention: Didactic intervention
Number of subjects: 2655
Study 27103421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered by trained psychosocial workers via telephone, based on Motivational Interviewing principles
Number of subjects: 144
Study 27103421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sessions
Number of subjects: 144
Study 27103421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity and acceptability of the intervention
Number of subjects: 144
Study 24859868 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic exercise intervention for 12 months
Number of subjects: 100
Study 24859868 — intervention group
Group type: COMPARATOR
Intervention: Stretching control for 12 months
Number of subjects: 100
Study 22978101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) therapy
Number of subjects: 91
Study 22978101 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 91
Study 22978101 — intervention group
Group type: EXPERIMENTAL
Intervention: CM + chemotherapy
Number of subjects: 91
Study 20466596 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (specific types not detailed)
Number of subjects: 0
Study 17435518 — intervention group
Group type: EXPERIMENTAL
Intervention: Menicon Z (MenZ; Dk/t = 91)
Number of subjects: 20
Study 17435518 — intervention group
Group type: EXPERIMENTAL
Intervention: Equalens II (EqII; Dk/t = 47)
Number of subjects: 20
Study 15996258 — intervention group
Group type: EXPERIMENTAL
Intervention: Split liver transplantation (SLT)
Number of subjects: 50
Study 15996258 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to share organs
Number of subjects: 50
Study 15996258 — intervention group
Group type: EXPERIMENTAL
Intervention: Priority for pediatric candidates
Number of subjects: 50
Study 12559281 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 1095
Study 12559281 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin plus finasteride
Number of subjects: 1095
Study 12559281 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 1095
Study 12559281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1095
Study 10233188 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM = omeprazole 20 mg b.d. + amoxycillin 1 g b.d. + metronidazole 500 mg b.d.
Number of subjects: 320
Study 10233188 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM = ranitidine 300 mg b.d. + amoxycillin 1 g b.d. + metronidazole 500 mg b.d.
Number of subjects: 320
Study 10233188 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC = omeprazole 20 mg b.d. + amoxycillin 1 g b.d. + clarithromycin 250 mg t.d.s.
Number of subjects: 320
Study 10233188 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC = ranitidine 300 mg b.d. + amoxycillin 1 g b.d. + clarithromycin 250 mg t.d.s.
Number of subjects: 320